Panacos Pharmaceuticals Inc. Announces Preliminary Results of Bevirimat Study 204

Published: Oct 28, 2008

WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (NASDAQ: PANC) announced today the bevirimat Study 204 achieved its primary objective by demonstrating bevirimat plasma levels in HIV-positive patients to be in a target range for virologic reduction. Bevirimat is a novel HIV-1 Gag maturation inhibitor in Phase 2b testing, and the data from the successful completion of this study will be used to optimize the bevirimat tablet dose for future Phase 2 as well as Phase 3 registration trials.

Back to news